Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 166, Issue 6, Pages 842-848
Publisher
Wiley
Online
2014-06-13
DOI
10.1111/bjh.12973
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide
- (2013) Vaishali Sanchorawala et al. AMERICAN JOURNAL OF HEMATOLOGY
- Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
- (2013) G. Palladini et al. HAEMATOLOGICA
- A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
- (2012) E. Kastritis et al. BLOOD
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
- (2012) S. K. Kumar et al. BLOOD
- A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
- (2012) G. Palladini et al. HAEMATOLOGICA
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
- (2012) R L Comenzo et al. LEUKEMIA
- Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
- (2011) Giovanni Palladini et al. ANNALS OF HEMATOLOGY
- Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
- (2011) M. T. Cibeira et al. BLOOD
- Outcome in Renal AL Amyloidosis After Chemotherapy
- (2011) Jennifer H. Pinney et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis
- (2010) V. Sanchorawala et al. BLOOD
- Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis
- (2010) U. Tapan et al. BLOOD
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
- (2010) P. Moreau et al. BLOOD
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
- (2010) Karl Bodin et al. NATURE
- Kidney dysfunction during lenalidomide treatment for AL amyloidosis
- (2010) R. Specter et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search